{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:19:27Z","timestamp":1790252367612,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,21]],"date-time":"2024-05-21T00:00:00Z","timestamp":1716249600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.jpba.2024.116248","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T15:30:03Z","timestamp":1716391803000},"page":"116248","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["First analytical confirmation of drug-induced crystal nephropathy in felines caused by GS-441524, the active metabolite of Remdesivir"],"prefix":"10.1016","volume":"247","author":[{"given":"Amelia","family":"Furbish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marissa","family":"Allinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenn","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Tynan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilee","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivette Pina","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2024.116248_bib1","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1517\/14740338.7.2.147","article-title":"Drug-induced crystal nephropathy: an update","volume":"7","author":"Yarlagadda","year":"2008","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jpba.2024.116248_bib2","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1517\/14740338.4.4.689","article-title":"Drug-induced nephropathy: an update","volume":"4","author":"Perazella","year":"2005","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jpba.2024.116248_bib3","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1016\/j.ekir.2021.09.003","article-title":"The crystalline nephropathies","volume":"6","author":"Perazella","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.jpba.2024.116248_bib4","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.2215\/CJN.11290821","article-title":"Drug-induced acute kidney injury","volume":"17","author":"Perazella","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/j.jpba.2024.116248_bib5","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40265-017-0853-7","article-title":"Drug-induced kidney stones and crystalline nephropathy: pathophysiology, prevention and treatment","volume":"78","author":"Daudon","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.jpba.2024.116248_bib6","article-title":"Preclinical pharmacokinetics and in vitro properties of GS-441524, a potential oral drug candidate for COVID-19 treatment","volume":"13","author":"Wang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jpba.2024.116248_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116364","article-title":"Potency and pharmacokinetics of GS-441524 derivatives against SARS-CoV-2","volume":"46","author":"Wei","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jpba.2024.116248_bib8","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1002\/psp4.12936","article-title":"Population pharmacokinetics and exposure-clinical outcome relationship of remdesivir major metabolite GS-441524 in patients with moderate and severe COVID-19","volume":"12","author":"Tamura","year":"2023","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"10.1016\/j.jpba.2024.116248_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00254-22","article-title":"Population pharmacokinetics of Remdesivir and GS-441524 in hospitalized COVID-19 patients","volume":"66","author":"Leegwater","year":"2022","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jpba.2024.116248_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2021.114118","article-title":"Validation of LC-MS\/MS methods for determination of remdesivir and its metabolites GS-441524 and GS-704277 in acidified human plasma and their application in COVID-19 related clinical studies","volume":"617","author":"Xiao","year":"2021","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.jpba.2024.116248_bib11","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.3390\/v13112228","article-title":"Curing cats with feline infectious peritonitis with an oral multi-component drug containing GS-441524","volume":"13","author":"Krentz","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.jpba.2024.116248_bib12","doi-asserted-by":"crossref","first-page":"9105","DOI":"10.1021\/acs.joc.3c00754","article-title":"Multistep synthesis of analogues of Remdesivir: incorporating heterocycles at the C-1' position","volume":"88","author":"Cardoza","year":"2023","journal-title":"J. Org. Chem."},{"key":"10.1016\/j.jpba.2024.116248_bib13","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/jvim.16954","article-title":"B.N. Louren\u00e7o, Uroliths composed of antiviral compound GS-441524 in 2 cats undergoing treatment for feline infectious peritonitis","volume":"38","author":"Allinder","year":"2024","journal-title":"J. Vet. Intern Med."},{"key":"10.1016\/j.jpba.2024.116248_bib14","doi-asserted-by":"crossref","first-page":"13224","DOI":"10.1039\/D3RA00654A","article-title":"Recent analytical methodologies for the determination of anti-covid-19 drug therapies in various matrices: a critical review","volume":"13","author":"Khalil","year":"2023","journal-title":"RSC Adv."},{"key":"10.1016\/j.jpba.2024.116248_bib15","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1007\/s00216-021-03561-8","article-title":"Quantitative HPLC-MS\/MS determination of Nuc, the active metabolite of remdesivir, and its pharmacokinetics in rat","volume":"413","author":"Du","year":"2021","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.jpba.2024.116248_bib16","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/jac\/dkaa152","article-title":"Development and validation of a UHPLC-MS\/MS method for quantification of the prodrug remdesivir and its metabolite GS-441524: a tool for clinical pharmacokinetics of SARS-CoV-2\/COVID-19 and Ebola virus disease","volume":"75","author":"Avataneo","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2024.116248_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.113935","article-title":"Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS\/MS method in human serum","volume":"196","author":"Habler","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116248_bib18","doi-asserted-by":"crossref","first-page":"7217","DOI":"10.1039\/D1NJ00160D","article-title":"Identification and characterization of degradation products of Remdesivir using liquid chromatography\/mass spectrometry","volume":"45","author":"Dadinaboyina","year":"2021","journal-title":"N. J. Chem."},{"key":"10.1016\/j.jpba.2024.116248_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jmsacl.2022.06.001","article-title":"Development and validation of a paper spray mass spectrometry method for the rapid quantitation of remdesivir and its active metabolite, GS-441524, in human plasma","volume":"25","author":"Skaggs","year":"2022","journal-title":"J. Mass Spectrom. Adv. Clin. Lab"},{"key":"10.1016\/j.jpba.2024.116248_bib20","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524002887?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524002887?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T06:38:27Z","timestamp":1720593507000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524002887"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":20,"alternative-id":["S0731708524002887"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116248","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"First analytical confirmation of drug-induced crystal nephropathy in felines caused by GS-441524, the active metabolite of Remdesivir","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116248","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116248"}}